InstalabOraRisk® HPV
Should you take a OraRisk® HPV test?
This test is most useful if any of these apply to you.
50 biomarkers included
- HPV Type 16The best-studied oral human papillomavirus signal. Type 16 causes most HPV-related cancers of the tonsils and base of tongue.Why it mattersRepeated positives make type 16 the result most worth acting on.
- HPV Type 18A vaccine-covered high-risk type. Its strongest cancer evidence is cervical, but persistent oral detection still belongs in follow-up.Why it mattersTreat repeat type 18 positives as high-risk, though it is less common orally than type 16.
- HPV Type 26A possible cancer-linked type found rarely in oral studies, included so uncommon high-risk detections are not missed.Why it mattersConfirm type 26 with repeat testing; persistence gives it more weight.
- HPV Type 30A possible cancer-linked type with sparse oral data, useful for identifying rare mucosal HPV rather than leaving it untyped.Why it mattersType 30 is best read with repeat results and any co-detected higher-risk types.
- HPV Type 31A high-risk type related to 16 and covered by the 9-valent vaccine.Why it mattersPersistent type 31 belongs on the high-risk non-16 follow-up track.
- HPV Type 33A high-risk vaccine-covered type in the same family as 16, with established cervical cancer evidence.Why it mattersRepeated type 33 positives mark a sustained high-risk mucosal infection.
- HPV Type 34A rare possible cancer-linked type, included to sort unusual oral detections from better-proven high-risk strains.Why it mattersA type 34 positive is unusual, so confirmation matters.
- HPV Type 35A high-risk type with cervical cancer evidence and a stronger signal in some studies of people of African ancestry.Why it mattersType 35 persistence matters, especially when types 16 and 18 are absent.
- HPV Type 39A high-risk type in the same broad group as 18, uncommon in oral samples.Why it mattersRepeat type 39 detection turns a one-time finding into a follow-up signal.
- HPV Type 45A high-risk vaccine-covered type related to 18 and included in extended cancer-risk typing.Why it mattersPersistent type 45 should be tracked like other high-risk results.
- HPV Type 51A high-risk type included in cervical assays; oral positives are uncommon but still worth separating from low-risk types.Why it mattersA repeat type 51 positive is more meaningful than a first detection.
- HPV Type 52A high-risk vaccine-covered type, more common in some Asian populations and included in many extended panels.Why it mattersPersistent type 52 supports closer follow-up, though oral cancer data are thinner than for type 16.
- HPV Type 53A possible cancer-linked type often treated as lower-risk than the main high-risk group.Why it mattersSerial type 53 results decide whether it is a sustained finding.
- HPV Type 56A high-risk type in cervical screening panels, usually less common in oral rinse studies.Why it mattersRetest to see whether type 56 clears or keeps appearing.
- HPV Type 58A high-risk vaccine-covered type related to 16, with higher prevalence in some East Asian populations.Why it mattersRepeated type 58 positives belong on the high-risk follow-up path.
- HPV Type 59A high-risk type related to 18 and 45, tracked because it can be cancer-linked at mucosal sites.Why it mattersFor type 59, persistence is the result that should change follow-up.
- HPV Type 64A lower-evidence mucosal type included for clear type identification when broad oral HPV is present.Why it mattersType 64 helps explain the positive result without making it a major cancer signal.
- HPV Type 66A high-risk type included in Food and Drug Administration-cleared cervical HPV assays, with weaker oral evidence than 16.Why it mattersRepeated type 66 positives carry more weight than a single detection.
- HPV Type 67A possible cancer-linked type in the 16-related family, rarely found in oral testing.Why it mattersRepeat testing separates persistent type 67 from a brief detection.
- HPV Type 68A high-risk type in cervical assays and a lower-frequency finding in oral samples.Why it mattersPersistent type 68 should stay on the high-risk follow-up list.
- HPV Type 69A possible cancer-linked type included to identify rare mucosal HPV detections.Why it mattersA repeat type 69 positive gives this rare finding its clinical weight.
- HPV Type 73A possible cancer-linked type tracked in oral natural-history studies as part of the high-risk spectrum.Why it mattersFor type 73, persistence matters more than one positive.
- HPV Type 82A possible cancer-linked type included in broad panels so uncommon mucosal infections are not missed.Why it mattersRepeat detection helps decide whether type 82 matters for follow-up.
- HPV Type 2aA skin-wart type that can appear in oral samples after hand-to-mouth or nearby skin exposure.Why it mattersType 2a points toward skin-wart exposure rather than a throat-cancer pathway.
- HPV Type 6A low-risk vaccine-covered type that causes many genital and oral wart-like lesions.Why it mattersA type 6 positive fits a wart-type pattern; look for visible papillomas if symptoms appear.
- HPV Type 11A low-risk vaccine-covered type tied to warts and recurrent respiratory papillomatosis.Why it mattersType 11 helps explain papilloma-type lesions without implying high-risk cancer biology.
- HPV Type 32The type classically linked to focal epithelial hyperplasia. This is a benign cluster of soft oral bumps.Why it mattersType 32 can explain soft, repeated oral bumps better than cancer risk.
- HPV Type 40A low-risk mucosal type occasionally found in oral and genital samples.Why it mattersType 40 sorts the result into a lower-risk mucosal strain.
- HPV Type 42A low-risk mucosal type often grouped with wart-associated HPV detections.Why it mattersType 42 points toward a benign lesion pathway, not throat-cancer risk.
- HPV Type 43A low-risk mucosal type seen in benign anogenital and occasional oral lesions.Why it mattersType 43 adds detail when a low-risk wart-family strain is present.
- HPV Type 44A low-risk mucosal type in the same clinical family as wart-associated types 6 and 11.Why it mattersA type 44 positive supports a benign wart-type interpretation.
- HPV Type 54A low-risk mucosal type reported in oral samples, useful for distinguishing non-high-risk HPV detections.Why it mattersType 54's main signal is strain identity, not cancer risk.
- HPV Type 55A low-risk mucosal type occasionally found in oral and genital samples.Why it mattersRepeat testing can show whether type 55 clears.
- HPV Type 57A skin-wart type that can be detected in oral rinses after contact exposure.Why it mattersType 57 points away from the main oral cancer-linked HPV types.
- HPV Type 61A low-risk mucosal type in the alpha-3 group, sometimes detected in healthy oral samples.Why it mattersType 61 gives a named low-risk explanation for a positive panel result.
- HPV Type 62A low-risk mucosal type often found in oral prevalence studies of healthy adults.Why it mattersType 62 usually tracks exposure rather than a cancer-risk pattern.
- HPV Type 70A lower-evidence mucosal type included because some classification systems flag possible cancer links.Why it mattersType 70 persistence is worth tracking, while one positive is usually lower concern.
- HPV Type 71A low-risk mucosal type detected in some normal oral rinse samples.Why it mattersType 71 helps classify a positive result as lower-risk mucosal HPV.
- HPV Type 72A low-risk mucosal type occasionally detected in healthy oral samples.Why it mattersA repeat type 72 result shows whether it is brief or persistent.
- HPV Type 74A low-risk mucosal type found in a subset of oral HPV surveys.Why it mattersType 74 adds resolution when the result is not a main high-risk strain.
- HPV Type 77A skin-wart type included because broad oral testing can detect skin HPV DNA.Why it mattersType 77 points toward skin-type exposure, not the usual throat-cancer types.
- HPV Type 81A low-risk mucosal type reported in oral rinse studies.Why it mattersType 81 helps separate low-risk oral HPV from high-risk strains.
- HPV Type 83A low-risk mucosal type occasionally identified in oral samples.Why it mattersType 83 is most useful as strain detail within a broad panel.
- HPV Type 84A low-risk mucosal type commonly included in oral natural-history studies.Why it mattersType 84 gives a specific low-risk label to an otherwise positive sample.
- HPV Type 89A low-risk mucosal type included to name less common oral HPV detections.Why it mattersType 89 marks a lower-risk oral HPV detection by name.
- HPV Type 41An unknown-risk type on the OraRisk report, included to avoid leaving rare detections unlabeled.Why it mattersType 41 gives you strain identity; persistence decides whether it deserves follow-up.
- HPV Type 49An unknown-risk type that can be picked up in broad oral HPV testing.Why it mattersType 49 is most useful for tracking the same rare type over time.
- HPV Type 60An unknown-risk skin-associated type most known outside the mouth, included for broad type coverage.Why it mattersA repeat positive can confirm whether type 60 is truly recurring.
- HPV Type 75An unknown-risk type included in complete typing panels for rare oral detections.Why it mattersType 75 labels uncommon positives that high-risk-only tests would miss.
- HPV Type 80An unknown-risk type occasionally found in broad HPV surveys.Why it mattersSerial testing tells whether type 80 disappears or keeps showing up.
About OraRisk® HPV
Human papillomavirus (HPV) is now behind about 60% to 70% of cancers that start in the tonsils and base of tongue in the United States. These cancers have risen sharply over the last few decades, especially in men. Most oral HPV infections cause no symptoms. That is why a saliva result is about risk and follow-up, not a diagnosis.
OraRisk HPV uses a 30-second swish-and-gargle oral rinse to look for DNA from 50 HPV types. The panel sorts results into high-risk, low-risk, and unknown-risk strains. It can't prove cancer is present, where the virus is sitting, or whether it will last. The useful question is narrower: which type showed up, and does it show up again?
What This Panel Reveals
The panel answers three questions from one sample. Is HPV detectable today? If so, is it a cancer-linked type, a wart-linked type, or a type whose oral-cancer meaning is not well worked out? And which strain is it? HPV 16 is not HPV 6. That distinction is the point of broad typing.
Type 16 is the main oral cancer signal. In a large prospective study, people with oral HPV 16 in mouthwash samples had about 22 times the later odds of cancer at the tonsils or base of tongue. That does not make one positive result a cancer warning. It means type 16 deserves a repeat test.
Other high-risk types in this panel are well-established causes of cervical cancer; their direct oral-cancer evidence is thinner. The panel still records them because a non-16 high-risk type is different from a wart-associated type. Low-risk types such as 6 and 11 point more toward warts or papillomas than cancer. Unknown-risk and skin-wart types are mainly useful because they tell you a detected virus is not type 16 or another better-proven cancer-linked strain.
One number keeps the panel in perspective. In a study of 7,674 adults across the United States and Europe, 1.8% to 4.5% of men carried a high-risk oral HPV type; for women, the range was 0.2% to 2.1%. So a positive high-risk result is not common, and most infections clear. The part worth watching is persistence.
How to Read Your Results Together
A single positive test is not the same as an infection that keeps showing up. Most newly acquired oral HPV infections clear within a year. In the HPV Infection in Men cohort, the median time to clearance was 6.9 months for any HPV and 7.3 months for HPV 16. Longer follow-up shows why repeat testing matters: in one 10-year cohort, 72.2% of people with oral HPV 16 detected at two consecutive visits had it persist long-term or developed HPV-related throat cancer, compared with 39.4% after one positive.
| Pattern | What It Suggests | Next Step |
|---|---|---|
| Negative for all types | No HPV DNA was found in this sample. It doesn't prove future immunity. | Retest in 1 to 3 years if you want ongoing surveillance. |
| Low-risk type only | A wart-linked type was found; this pattern is not the one tied to throat cancer. | Check your mouth and keep routine dental exams; remove visible papillomas if they appear. |
| Unknown-risk or skin-wart type | The result explains which strain was detected without turning it into a cancer signal. | Repeat only if it persists, symptoms appear, or you want confirmation. |
| High-risk non-16 type, first positive | A cancer-linked type was found, but many first positives clear. | Retest in 6 to 12 months. |
| HPV 16 positive, first positive | The highest-risk oral type was found. One result still can't diagnose cancer. | Repeat in 6 to 12 months and get a careful oral and neck exam. |
| Any high-risk type on repeat testing | The same risk-linked type keeps showing up, which is more concerning than one positive. | Use closer follow-up with a dentist or ear, nose, and throat specialist. |
What to Do with Your Results
A negative result is reassuring for today. It is not permanent. Oral HPV can be acquired at any age through oral sex, and the amount of virus in the mouth can come and go. Retest if your risk profile changes or every 1 to 3 years if you want ongoing surveillance.
A positive result is not a cancer diagnosis and should not be treated like one. There is no antiviral drug that clears HPV; the immune system usually does that on its own. The next move is a careful oral and head-and-neck exam by a dentist or ear, nose, and throat specialist, especially if you have a visible lesion, neck lump, trouble swallowing, or a persistent sore throat. Then repeat the saliva test in 6 to 12 months. Persistence, especially of HPV 16, is the signal that deserves closer follow-up.
If you haven't been vaccinated, the HPV vaccine is the best proven step against new vaccine-type infections. It is routinely recommended through age 26 in the United States, and some adults 27 to 45 can still choose it. It protects against the highest-risk types, including 16 and 18, but it does not clear an infection you already have.
When Results Can Be Misleading
Oral HPV detection is intermittent. During known persistent infections, a meaningful share of individual visits still return a negative test, and clearance definitions strongly shape what counts as persistent. That is why one negative sample can miss an infection that is really there.
An oral rinse also cannot map the exact site of infection. It may not sample the deep tonsil and tongue-base tissue where many HPV-related cancers start. Meta-analysis data show the same problem from another angle: oral rinse HPV testing misses a meaningful share of HPV-related head and neck cancers in people already being evaluated. Recent oral sex, brushing, mouthwash, eating, or drinking before collection can also affect the sample. Follow the collection instructions closely, and treat a single result as a snapshot.
Where This Panel Fits on the Evidence Ladder
No major medical society recommends routine oral HPV screening for adults without symptoms. The Centers for Disease Control and Prevention says there is no approved test for HPV in the mouth or throat. Food and Drug Administration-cleared HPV tests are cervical tests; they should not be used for oral specimens.
There is human outcome evidence behind the core signal, especially oral HPV 16 and later throat cancer risk. But this is not a validated cancer screen. In pooled data, oral rinse HPV testing had about 91% specificity but only about 68% sensitivity for HPV-related head and neck cancer in people already being evaluated. The practical result: it missed about a third of true cases. Use this panel as a risk-awareness and follow-up tool, not as a verdict.